Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of EMD 1201081 + cetuximab versus cetuximab alone in recurrent or metastatic head and neck squamous cell carcinoma
2009-014440-10Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing EMD 1201081 + cetuximab with cetuximab alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2009; status: completed.
02
Drugs
IMO-2055cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-014440-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014440-10.